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Vasculature analysis of patient derived tumor
xenografts using species-specific PCR assays:
evidence of tumor endothelial cells and atypical
VEGFA-VEGFR1/2 signalings
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Abstract
Background: Tumor endothelial transdifferentiation and VEGFR1/2 expression by cancer cells have been reported
in glioblastoma but remain poorly documented for many other cancer types.
Methods: To characterize vasculature of patient-derived tumor xenografts (PDXs), largely used in preclinical
anti-angiogenic assays, we designed here species-specific real-time quantitative RT-PCR assays. Human and mouse
PECAM1/CD31, ENG/CD105, FLT1/VEGFR1, KDR/VEGFR2 and VEGFA transcripts were analyzed in a large series of 150 PDXs
established from 8 different tumor types (53 colorectal, 14 ovarian, 39 breast and 15 renal cell cancers, 6 small cell and 5
non small cell lung carcinomas, 13 cutaneous melanomas and 5 glioblastomas) and in two bevacizumab-treated non
small cell lung carcinomas xenografts.
Results: As expected, mouse cell proportion in PDXs -evaluated by quantifying expression of the housekeeping gene
TBP- correlated with all mouse endothelial markers and human VEGFA RNA levels. More interestingly, we observed
human PECAM1/CD31 and ENG/CD105 expression in all tumor types, with higher rate in glioblastoma and renal cancer
xenografts. Human VEGFR expression profile varied widely depending on tumor types with particularly high levels of
human FLT1/VEGFR1 transcripts in colon cancers and non small cell lung carcinomas, and upper levels of human KDR/
VEGFR2 transcripts in non small cell lung carcinomas. Bevacizumab treatment induced significant low expression of
mouse Pecam1/Cd31, Eng/Cd105, Flt1/Vegfr1 and Kdr/Vefr2 while the human PECAM1/CD31 and VEGFA were upregulated.
Conclusions: Taken together, our results strongly suggest existence of human tumor endothelial cells in all tumor types
tested and of both stromal and tumoral autocrine VEGFA-VEGFR1/2 signalings. These findings should be considered
when evaluating molecular mechanisms of preclinical response and resistance to tumor anti-angiogenic strategies.
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Background
Tumor vasculature, a crucial feature in cancer develop-
ment and progression, is based on angiogenesis and vas-
culogenesis driven by VEGF signalings [1-3] but also on
tumor endothelial transdifferentiation and vascular mim-
icry [4]. The VEGFR1 and VEGFR2 tyrosine kinase recep-
tors are primarily expressed by endothelial cells. Recent
studies, however, suggest that tumor-derived VEGF pro-
vides not only paracrine survival cues for endothelial cells,
but may also autocrine processes in tumor cells expressing
VEGFRs and play a role in tumor resistance to existing
anti-angiogenic therapies [5-7].
Growth of patient tumor fragments into immunodefi-
cient mice allows an accurate depiction of human tumor
biological characteristics and are considered to represent
the heterogeneity of human cancers (for review [8]). These
patient-derived tumor xenografts (PDX) are greatly helpful
to evaluate fundamental issues in cancer and chemosensi-
tivity response, including characteristics of angiogenesis,
tumor-stroma interactions and response to antiangiogenic
therapies. As real-time quantitative RT-PCR is highly spe-
cific, species-specific primer sets can allow to discriminat-
ing between mouse/stromal and human/cancer gene
expression in PDX models.
To obtain further insight into tumor vascularization
and VEGFR expression by cancer and non-tumor cells,
we used real-time qRT-PCR to quantify species-specific
mRNAs of PECAM1/CD31, ENG/CD105, FLT1/VEGFR1,
KDR/VEGFR2 and VEGFA genes in a large series of 150
xenografts from different tumor types. We also validated
clinical relevance of species-specific PCR assays for in vivo
evaluation of anti-angiogenesis therapy in two non small
cell lung carcinoma models. We showed human PECAM1/
CD31 and ENG/CD105 expression in all tumor types, sup-
porting existence of human tumor endothelial cells in all
tumor types. In addition, the VEGFR expression profiles
led to involvement of both stromal and tumoral autocrine
VEGFA-VEGFR1/2 signalings in tumors.
Results and discussion
First, the proportion of mouse cells was estimated in a
panel of 8 different PDX types, using a real-time qRT-
PCR assay combining primers specific for mouse Tbp
RNA and primers able to amplify a common sequence
on both human and mouse TBP transcripts. (Additional
file 1: Table S1). As this gene encoding the TATA box-
binding protein is a robust house-keeping gene [9] with
similar amplification efficiency for the 2 primer sets, the
ratio reflects the percentage of mouse cells within xeno-
graft as validated in a standard curve of mouse and hu-
man cDNA mixtures (data not shown).
In an initial series of 157 human xenografts, the pro-
portion of mouse cells was 100% in 7 tumors. These
7 tumor samples probably originated from spontaneous
mouse lymphoma, frequently observed in immunodeficient
mice [10].
In the 150 other xenografts, mouse host cells were
found in all specimens with a median proportion of
mouse cells of 9%, ranged between 3.3% in SCLC and
20% in NSCLC (p < 0.05, Table 1). To note, all the xeno-
grafts used here, have been passaged at least 5 times in
mice, leading to a replacement of human stroma by
mouse components [8].
Mouse cells encompass here a wide range of stromal
cell types, including fibroblasts, inflammatory and im-
mune cells, smooth muscle cells, and endothelial cells.
We further focused on endothelial cells using expression
of mouse Pecam1/Cd31 and Eng/Cd105 genes (herein-
after referred to as mCd31 and mCd105, respectively) to
evaluate their proportion within xenografts. Vwf gene
encoding von Willebrand factor was also preliminary
selected but not kept because of a lower expression rate
in the mouse and human controls (Ct > 30, data not
shown).
As expected, all samples, collected from large xenografts
without necrotic centre, expressed mCd31 and mCd105
genes. Nevertheless, mCd31 and mCd105 mRNA levels
widely varied between the samples (Table 1), but remained
highly correlated to each other (p < 10-7; Table 2). Note-
worthy, mCd31 and mCd105 expression levels were highly
correlated with the proportion of mouse cells (Table 2),
suggesting that the relative amount of endothelial cells
remains stable within diverse stromal cell populations,
whatever the density of stroma component and the cancer
type.
While numerous pro-angiogenic factors have been
characterized, the VEGFA ligand has been identified as a
predominant regulator of tumor angiogenesis and binds
to VEGFR1 and VEGFR2 expressed on vascular endo-
thelial cells. It mediates numerous changes within the
tumor vasculature, including endothelial cell prolifera-
tion, migration, invasion, survival, chemotaxis of bone
marrow-derived progenitor cells, vascular permeability
and vasodilatation [1,2]. VEGFA expression by cancer
cells is up-regulated by altered expression of oncogenes,
a variety of growth factors and also hypoxia [2].
Unsurprisingly, we observed high levels of mouse Flt1/
Vegfr1, mouse Kdr/Vegfr2 (hereby denominated mVegfr1
and mVegfr2) and human VEGFA (hVEGFA) transcripts,
which correlated all with mCd31 and mCd105 RNA levels
(Table 2). These strong positive correlations underline
classical paracrine VEGFA-VEGFR1/2 signaling in tumori-
genesis and crosstalk between the human ligand and
mouse receptors. Expression of mVegfr1, mVegfr2 and
hVEGFA however varied widely in the different tumor
types. RCC, glioblastoma and NSCLC xenografts showed
transcript level median of these three genes at least 2 times
higher than in the 5 other tumor xenograft types (Table 1,
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Table 1 Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)
Sample nature Derived from
primary tumor
or metastatis
% of mouse
cells
PECAM1 ENG VEGFR1 VEGFR2 VEGFA % of mVegfa vs
human + mouse
VEGFA transcripts
Hs Mm Hs Mm Hs Mm Hs Mm Hs Mm
Pure human control 0% 1265 0 796 0 2610 0 157 0 287 0
Pure mouse control 100% 0 1176 0 736 0 303 0 879 0 790
Colorectal carcinoma PDX
CRC#1 Primary 11% 0 894 2 492 23 453 0 405 4010 212 5%
CRC#2 Primary 5% 0 917 3 398 9 383 0 309 4912 51 1%
CRC#3 Metastasis 21% 1 2380 34 893 14 843 0 803 4642 628 12%
CRC#4 Primary 17% 0 836 <1 285 0 368 0 299 2876 302 10%
CRC#5 Metastasis 8% 0 813 0 492 3 337 0 374 3552 109 3%
CRC#6 Primary 9% 46 458 217 326 77 196 <1 176 1866 84 4%
CRC#7 Metastasis 8% 17 553 27 272 65 292 0 210 5230 251 5%
CRC#8 Primary 14% 0 1193 469 614 3 349 0 689 2999 92 3%
CRC#9 Primary 8% 0 967 8 550 3 475 0 379 7973 204 2%
CRC#10 Primary 10% 0 733 <1 409 176 246 0 284 3463 124 3%
CRC#11 Metastasis 9% 1 1083 <1 481 300 567 0 410 5461 135 2%
CRC#12 Metastasis 4% 48 479 0 182 26 274 0 230 4937 106 2%
CRC#13 Metastasis 4% 3 356 5 135 289 163 0 168 3606 145 4%
CRC#14 Primary 2% <1 260 7 139 305 119 0 143 5085 76 1%
CRC#15 Primary 17% <1 1287 <1 715 51 530 0 419 6541 311 5%
CRC#16 Metastasis 5% <1 477 44 237 89 197 0 219 3406 196 5%
CRC#17 Primary 17% 21 1067 49 539 42 382 0 323 3674 555 13%
CRC#18 Primary 14% 4 1078 81 550 33 370 <1 356 2016 262 12%
CRC#19 Primary 4% 3 288 <1 162 <1 120 0 135 4258 111 3%
CRC#20 Metastasis 22% 4 1580 19 754 10 584 <1 684 5604 391 7%
CRC#21 Metastasis 17% 10 1336 373 749 10 656 0 639 4894 432 8%
CRC#22 Primary 18% 0 2315 322 1081 32 908 0 1262 4671 1244 21%
CRC#23 Metastasis 8% 0 446 407 406 42 202 0 173 2360 155 6%
CRC#24 Primary 12% 0 981 5 581 13 508 0 331 4773 233 5%
CRC#25 Primary 5% 0 622 36 329 0 246 0 285 2643 68 3%
CRC#26 Primary 11% 0 1245 569 480 112 375 0 296 3607 237 6%
CRC#27 Primary 14% 4 1789 3 895 83 682 0 581 3101 891 22%
CRC#28 Carcinosis 5% 3 526 1 326 1 215 0 268 2545 29 1%
CRC#29 Primary 11% 5 1000 2 541 0 364 0 344 3172 391 11%
CRC#30 Primary 7% 0 753 11 332 22 282 0 258 2247 231 9%
CRC#31 Metastasis 10% <1 629 1 294 29 241 0 216 2896 210 7%
CRC#32 Primary 16% 0 1073 304 556 28 357 0 469 1731 166 9%
CRC#33 Primary 7% 4 563 <1 277 7 202 0 218 1253 129 9%
CRC#34 Primary 13% 2 749 379 530 15 306 0 390 4293 157 4%
CRC#35 Primary 9% 0 958 3 484 9 329 0 318 2206 212 9%
CRC#36 Primary 21% 1 991 0 504 32 388 <1 436 3296 140 4%
CRC#37 Primary 19% 6 1978 16 840 10 391 0 668 2692 182 6%
CRC#38 Primary 8% 2 1114 8 446 2 320 0 367 1889 218 10%
CRC#39 Metastasis 12% 0 1156 478 523 40 366 0 418 4034 214 5%
CRC#40 Primary 10% <1 547 94 356 49 199 0 242 1848 142 7%
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Table 1 Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)
(Continued)
Sample nature Derived from
primary tumor
or metastatis
% of mouse
cells
PECAM1 ENG VEGFR1 VEGFR2 VEGFA % of mVegfa vs
human + mouse
VEGFA transcripts
Hs Mm Hs Mm Hs Mm Hs Mm Hs Mm
CRC#41 Carcinosis 16% 0 1552 3 762 7 325 0 457 918 228 20%
CRC#42 Primary 31% 0 1786 <1 922 94 447 0 599 2710 493 15%
CRC#43 Primary 10% 0 1024 75 459 249 358 2 431 4126 272 6%
CRC#44 Carcinosis 15% <1 938 159 565 1 285 0 364 2523 269 10%
CRC#45 Primary 12% 1654 807 512 388 9 215 1 332 969 124 11%
CRC#46 Primary 3% <1 412 3 158 2 139 0 168 1865 61 3%
CRC#47 Metastasis 6% 0 521 2 252 <1 173 0 195 1662 68 4%
CRC#48 Carcinosis 10% 0 843 <1 417 0 252 0 252 1705 227 12%
CRC#49 Metastasis 6% 1 379 426 274 11 248 0 267 4587 149 3%
CRC#50 Metastasis 18% 31 1697 0 690 23 485 0 421 5271 299 5%
CRC#51 Primary 23% 0 1294 2 662 67 476 0 375 6660 583 8%
CRC#52 Primary 38% 14 3265 398 1126 640 736 0 836 7517 953 11%
CRC#53 Metastasis 19% 0 1657 0 566 15 430 0 430 4014 209 5%
Median 10.6% 0.7 958 7 484 22 349 0 344 3463 210 6%
Ovarian carcinoma PDX
OVC#1 Metastasis 28% 42 2575 0 1498 89 1191 159 867 10390 459 4%
OVC#2 Metastasis 5% 4 565 99 350 2 439 34 259 6391 88 1%
OVC#3 Metastasis 21% 1 1427 304 809 69 406 <1 583 3133 710 18%
OVC#4 Primary 6% 26 709 9 474 0 259 4 272 1528 144 9%
OVC#5 Primary 7% 16 974 81 807 0 802 45 525 14226 95 1%
OVC#6 Primary 12% 3 2052 97 593 19 734 101 528 2628 427 14%
OVC#7 Primary 8% 0 762 4 470 0 270 32 278 6156 266 4%
OVC#8 Primary 3% 2 219 30 119 6 88.8 3 59.2 652 37 5%
OVC#9 Primary 8% 5 1795 2 674 3 518 5 372 2981 184 6%
OVC#10 Primary 4% 1 444 16 288 0 204 22 141 2812 52 2%
OVC#11 Primary 20% 24 1586 54 1036 0 482 2 648 2781 493 15%
OVC#12 Primary 13% 3 877 177 487 0 259 12 285 1720 127 7%
OVC#13 Primary 3% 17 550 207 263 2 196 <1 224 1134 16 1%
OVC#14 Primary 5% 0 332 <1 255 21 238 <1 164 19239 62 0%
Median 7% 3.7 819 42 480 2 338 9 281 2896 136 5%
Glioblastoma PDX
GBM#1 Primary 8% 22 712 2051 457 378 559 8 186 18822 241 1%
GBM#2 Primary 13% 1 1351 1143 819 0 799 378 328 17084 296 2%
GBM#3 Primary 13% 1 2372 422 1184 0 1325 0 1237 8452 131 2%
GBM#4 Primary 5% 55 870 321 328 0 503 0 372 5923 78 1%
GBM#5 Primary 15% 0 2600 268 1389 28 1361 294 1413 15443 100 1%
Median 13% 1.4 1351 422 819 0 799 8 372 15443 131 1%
Breast cancer carcinoma PDX
BC#1 Primary 2% <1 222 204 113 3 89.4 2 80.7 637 114 15%
BC#2 Primary 8% 0 666 177 335 19 289 0 162 2997 310 9%
BC#3 Metastasis 10% 0 679 286 447 5 539 36 259 4961 334 6%
BC#4 Primary 15% 46 803 91 498 5 366 0 222 3547 447 11%
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Table 1 Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)
(Continued)
Sample nature Derived from
primary tumor
or metastatis
% of mouse
cells
PECAM1 ENG VEGFR1 VEGFR2 VEGFA % of mVegfa vs
human + mouse
VEGFA transcripts
Hs Mm Hs Mm Hs Mm Hs Mm Hs Mm
BC#5 Primary 1% <1 116 0 61.9 33 89.1 4 31.9 15066 77 1%
BC#6 Metastasis 15% 2 1351 289 634 29 719 150 439 17360 357 2%
BC#7 Primary 22% 8 1908 442 887 0 1370 0 739 27659 365 1%
BC#8 Primary 6% 1 810 149 412 18 327 9 280 8360 160 2%
BC#9 Metastasis 10% 0 713 6 322 13 420 0 279 1020 294 22%
BC#10 Primary 6% 3 370 460 233 0 325 17 134 7447 154 2%
BC#11 Primary 6% 6 993 347 403 29 461 68 325 14282 256 2%
BC#12 Primary 8% 6 1005 466 543 28 664 3 391 25794 363 1%
BC#13 Primary 7% 0 575 92 256 8 266 15 189 6174 132 2%
BC#14 Primary 8% 654 745 45 413 0 279 2 253 3294 71 2%
BC#15 Metastasis 11% 4 912 50 461 1 311 0 286 3458 186 5%
BC#16 Primary 2% 0 199 188 94.6 4 73.6 2 69.7 610 100 14%
BC#17 Primary 4% 13 413 346 134 66 173 32 101 2131 197 8%
BC#18 Primary 10% <1 1545 168 743 3 788 11 382 6550 167 2%
BC#19 Metastasis 16% <1 2304 167 1188 5 1049 10 771 6004 280 4%
BC#20 Primary 17% 0 1967 340 959 1 709 20 634 11533 357 3%
BC#21 Primary 9% 0 730 334 332 2 476 91 202 8166 520 6%
BC#22 Primary 6% 0 598 451 222 10 334 90 124 5088 264 5%
BC#23 Primary 4% 0 377 331 179 2 195 19 83.3 1742 51 3%
BC#24 Primary 22% 1 1128 858 982 79 999 <1 495 21363 668 3%
BC#25 Primary 10% 0 1165 666 573 94 627 12 474 14542 244 2%
BC#26 Primary 10% 0 1446 429 572 0 685 230 510 5771 257 4%
BC#27 Primary 14% 2 880 4 452 94 415 <1 222 1505 299 17%
BC#28 Primary 5% <1 182 91 113 7 119 6 80.3 1221 50 4%
BC#29 Primary 9% <1 656 530 469 32 532 9 473 50360 255 1%
BC#30 Primary 7% 3 823 94 341 247 403 34 244 9097 373 4%
BC#31 Primary 4% 0 345 166 216 0 161 3 145 1085 79 7%
BC#32 Primary 7% <1 629 13 276 4 237 19 194 1544 198 11%
BC#33 Primary 9% <1 725 397 428 232 549 6 231 5414 144 3%
BC#34 Primary 14% 5 1061 245 557 0 457 0 308 3866 176 4%
BC#35 Primary 5% 2 484 103 358 3 506 50 185 23896 360 1%
BC#36 Primary 13% 0 1085 221 544 0 333 13 347 1153 231 17%
BC#37 Primary 4% 0 376 193 149 <1 144 13 120 1081 289 21%
BC#38 Primary 6% 2 776 90 415 8 326 12 281 4683 178 4%
BC#39 Primary 14% 0 961 5 731 83 691 4 606 4829 152 3%
Median 7.9% 0.7 745 193 413 5 403 10 253 5088 244 4%
Cutaneous melanoma PDX
CM#1 Metastasis 11% 0 1725 2985 825 0 953 83 1026 10386 1401 12%
CM#2 Metastasis 7% 27 544 1391 426 768 360 0 184 10696 315 3%
CM#3 Metastasis 4% 1 282 257 180 0 122 1 155 599 102 14%
CM#4 Primary 20% 0 3306 784 1178 427 883 38 836 9188 718 7%
CM#5 Metastasis 8% 9 936 872 363 15 587 0 289 5590 201 3%
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Table 1 Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)
(Continued)
Sample nature Derived from
primary tumor
or metastatis
% of mouse
cells
PECAM1 ENG VEGFR1 VEGFR2 VEGFA % of mVegfa vs
human + mouse
VEGFA transcripts
Hs Mm Hs Mm Hs Mm Hs Mm Hs Mm
CM#6 Metastasis 3% <1 342 648 196 6 188 5 236 960 23 2%
CM#7 Metastasis 1% 2 176 382 83.6 2 135 <1 84.3 5962 37 1%
CM#8 Primary 10% 9 4760 876 705 0 2230 5 841 16732 239 1%
CM#9 Metastasis 1% 0 118 284 61.6 20 125 14 73.6 3704 24 1%
CM#10 Primary 10% 0 876 756 300 0 248 279 285 387 126 25%
CM#11 Metastasis 8% 2 641 1102 427 0 355 1 309 8837 266 3%
CM#12 Primary 5% 0 530 112 186 0 440 0 423 683 26 4%
CM#13 Metastasis 2% <1 243 145 101 <1 116 1 82.2 466 31 6%
Median 7.1% 0.9 544 756 300 0.8 355 1 285 5590 126 3%
Renal cell carcinoma PDX
RCC#1 Primary 17% 0 1179 569 1002 0 680 2 473 19769 1513 7%
RCC#2 Primary 12% 0 3362 16 1929 0 1934 0 3043 27096 54 0%
RCC#3 Primary 27% 0 5431 411 2376 0 1866 0 1974 25792 211 1%
RCC#4 Metastasis 11% 120 2117 256 1430 4 1512 0 1337 13968 89 1%
RCC#5 Primary 16% 5 2906 33 1942 3 1624 0 2102 25817 87 0%
RCC#6 Primary 1% 1 341 2 125 2 157 47 119 609 13 2%
RCC#7 Primary 21% 0 768 549 1908 0 1292 0 1324 27232 157 1%
RCC#8 Metastasis 17% 1 842 410 778 0 466 0 286 1756 930 35%
RCC#9 Metastasis 13% 17 2024 230 1258 3 827 1 904 37839 55 0%
RCC#10 Primary 11% 0 2010 856 1359 0 1070 2 672 37217 83 0%
RCC#11 Primary 5% 2 597 907 350 0 487 0 253 5091 136 3%
RCC#12 Metastasis 14% 0 2546 257 1132 0 871 0 1040 16952 61 0%
RCC#13 Primary 21% 0 4963 38 3466 0 3281 0 3966 30645 155 1%
RCC#14 Primary 6% 330 1338 364 602 0 661 2 343 26952 52 0%
RCC#15 Primary 6% 77 565 1036 293 0 368 0 291 2210 59 3%
Median 12.9% 1.2 2010 364 1258 0 871 0 904 25792 87 1%
Lung carcinoma PDX
Small cell lung carcinoma
SCLC#1 Primary 8% 0 1030 3 387 0 250 0 196 419 43 9%
SCLC#2 Primary 3% 2 632 0 238 5 189 0 185 1300 52 4%
SCLC#3 Primary 4% 4 591 0 259 1 232 2 232 1117 49 4%
SCLC#4 Primary 3% 7 395 0 222 0 166 0 162 1498 46 3%
SCLC#5 Metastasis 2% 0 309 1 153 0 160 2 122 893 56 6%
SCLC#6 Primary 7% 2 670 9 221 471 208 72 192 954 86 8%
Median 3.3% 1.7 612 0 230 1 198 1 189 1035 51 5%
Non small cell lung carcinoma
NSCLC#1 Primary 28% 3 1969 61 941 2 1145 14 637 18440 794 4%
NSCLC#2 Primary 8% 0 1270 0 611 0 511 335 639 5911 98 2%
NSCLC#3 Primary 22% 95 1590 31 1438 124 961 930 669 18346 429 2%
NSCLC#4 Primary 5% 2 686 5 339 4 212 59 221 875 85 9%
NSCLC#5 Primary 20% 3 1363 667 1387 184 896 3106 652 10612 688 6%
Median 20% 2.7 1363 31 941 4 896 335 639 10612 429 4%
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Figure 1). According to the expression level of mCd105,
mCd31, mVegfr1, mVegfr2 and hVEGFA (Figure 1), the
most angiogenic PDXs are then renal cell carcinoma,
glioblastoma, and NSCLs, tumor types well-known to be
the most angiogenic tumors in patients [11], underlying
the interest of PDX models to mimic patient tumors.
Surprisingly, we observed also marked level of mVegfa
transcripts ranged from 50.7 (median in SCLC xeno-
grafts) to 429 (median in NSCLC xenografts). Individu-
ally, some xenografts showed more than 20% of the total
VEGFA transcripts of mouse origin (Table 1). While
VEGFA production by cancer cells is commonly reported,
significant VEGFA expression has been also observed by
fibroblasts and immune cells that surround and invade the
tumor mass [12]. As reported by others [13], great atten-
tion has to be paid to mouse stromal VEGFA when anti-
VEGF agents displaying specific human activity are tested
in xenograft preclinical models.
Angiogenesis and vasculogenesis, mediated by angio-
genic factors such as VEGFA are commonly accepted
to support tumor vasculature. Vascular mimicry (ability
of tumor cells to form functional vessel-like networks,
devoid of endothelial cells) and cancer stem cell transdif-
ferentiation into tumor endothelial cells are also two
mechanisms recently reported in different tumors, in-
cluding melanoma, breast, renal, ovarian cancer and
glioblastoma [14-18] in which tumor cells directly par-
ticipate in vascular channels. The presence of tumor-
derived endothelial cells (TDECs) is usually investigated
through the detection of CD31+ and CD105+ tumor cells
[15-18]. TDEC cells are generally rare events and their
identification needs highly sensitive methods (flow cytom-
etry or confocal microscopy). Likewise, another approach
to improving the detection of TDEC is to enhance the
TDEC frequency by implanting into mice cancer stem cell
enriched population. This prior enrichment could be done
Table 2 Relationships between mouse (m) and human (h) mRNA levels in the 150 human tumor xenografts
hCD31 mCd31 hCD105 mCd105 hVEGFR1 mVegfr1 hVEGFR2 mVegfr2 hVEGFA mVegfa
mCd31 0.0251
0.762
hCD105 0.043 0.121
0.60 0.14
mCd105 0.040 0.928 0.189
0.63 <0.0000001 0.02
hVEGFR1 0.065 0.022 -0.076 0.004
0.43 0.79 0.35 0.96
mVegfr1 0.076 0.851 0.305 0.877 0.006
0.35 <0.0000001 <0.0002 <0.0000001 0.94
hVEGFR2 0.010 -0.029 0.232 -0.036 -0.036 0.070
0.91 0.72 <0.005 0.66 0.66 0.40
mVegfr2 0.003 0.912 0.173 0.919 -0.017 0.858 -0.090
0.98 <0.0000001 <0.05 <0.0000001 0.83 <0.0000001 0.27
hVEGFA 0.095 0.477 0.319 0.563 0.090 0.726 0.131 0.517
0.25 <0.0000001 <0.0002 <0.0000001 0.27 <0.0000001 0.11 <0.0000001
mVegfa 0.031 0.505 0.194 0.524 0.304 0.514 0.062 0.413 0.328
0.70 <0.0000001 <0.05 <0.0000001 <0.0002 <0.0000001 0.45 <0.0000001 <0.00005
% mouse cells -0.016 0.828 0.113 0.865 0.154 0.715 -0.145 0.797 0.364 0.666
0.84 <0.0000001 0.17 <0.0000001 0.06 <0.0000001 0.08 <0.0000001 <0.000005 <0.0000001
Results, expressed as N-fold differences in target gene expression relative to the mouse and human TBP genes (both the mouse and human TBP transcripts) and
termed “Ntarget”, were determined as Ntarget = 2∆Ctsample , where the ∆Ct value of the sample was determined by subtracting the average Ct value of target gene
(human or mouse) from the average Ct value of ‘Total-TBP’ gene). The Ntarget values of the tumor samples were subsequently normalized such that the value for
mRNA level was 1 when Ct=35. Target mRNA levels that were total absence or very low (Ct > 38) in tumor samples were scored ‘0’ for non expressed. As
for calculation of % of mouse cells, specific mouse Tbp gene expression and the expression of both the mouse and the human TBP genes were studied by
real-time qRT-PCR using the mouse Tbp as target gene and the ‘Total-TBP’ as endogenous RNA control. Results, expressed as N-fold differences in specific
mouse Tbp gene expression (using mouse Tbp primers) relative to the sum of the mouse and the human TBP gene expression (using ‘Total-TBP’ primers),
termed NMm-TBP, are determined by theformula: NMm-TBP = 2DCtsample. The DCt value of the sample is determined by subtracting the Ct value of the mouse
TBP gene from the Ct value of the Total TBP gene. The NMm-TBP values of the samples are subsequently normalized such that the median of NMm-TBP
values of 4 mouse tissues was 100. As TBP is a ubiquitously expressed housekeeping gene, showing similar expression in our human and mouse tissues
(Ct=27 for 5 ng cDNA), the final result (normalized NMm-TBP value) gives an estimate of the proportion of mouse cell content for a given xenograft. 1Spearman
correlation coefficient, 2p value of Spearman rank correlation test, in bold when p is significant.
Bieche et al. BMC Cancer 2014, 14:178 Page 7 of 13
http://www.biomedcentral.com/1471-2407/14/178
by culturing cells as tumor spheres [19,20] or by cell sort-
ing for putative cancer stem cell markers [15,21]. Only
one recent publication attempted to immunostain human
CD31 directly in 3 human tumor xenografts, with no pre-
liminary step of TDEC or CSC enrichment [22]. This
study did not detect human CD31 and led the authors to
conclude that endothelial cells in human hepatocellular
carcinoma xenografts are of mouse rather than human
origin, but did not allow them to absolutely exclude this
possibility. Consequently, we apply in our PDX panel the
real-time qRT-PCR method, known for its very high sensi-
tivity, using human-specific PECAM1/CD31 (hCD31) and
ENG/CD105 (hCD105) to gain more insight into TDECs.
Surprisingly, we detected hCD31 and hCD105 tran-
scripts in all types of PDXs, suggesting that TDECs can
exist in virtually all types of cancer. The possibility of
human endothelial marker signals due to very rare
remaining human stroma cells can not be ignored, al-
though the whole human stroma in tumor xenografts is
reported to be eventually replaced by stroma of mouse
origin [8,23,24]. But depending upon the types, the range
of expression of hCD31 and hCD105 transcripts largely
varied (Figure 2a-b). All tested samples of cutaneous
melananoma and GBM highly expressed hCD105 gene
(NHs-ENG >100). Literature indeed reports a large ex-
pression of CD105, a member of the transforming growth
factor beta receptor family, on normal and neoplastic cells
of the melanocytic lineage, including melanoma cell lines,
and an up-regulation in gene signature of aggressive
cutaneous melanoma in patients [14]. Likewise, CD105
is highly expressed in glioblastoma but essentially ab-
sent in normal brain [21]. RCC xenografts displayed a
great proportion of samples expressed high levels of
hCD31 or hCD105. These results fit with the literature
that identified TDECs in patients mainly in glioblast-
oma and renal cancer [16,21]. By contrast, SCLCs show
very low levels of both hCD31 and hCD105 mRNAs. A
striking point is that hCD31 and hCD105 RNA levels
did not correlate to each others (Table 2), even if their
expression is analyzed for each cancer type (data not
shown). It could be explained by different expression
profiles for these 2 endothelial molecules: CD31 is con-
sidered as a pan-endothelial marker, whereas CD105 is
a cell membrane glycoprotein predominantly expressed
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Figure 1 Gene expression levels of mouse endothelial markers and hVEGFA in the 8 human tumor xenograft types. Box-and-whisker
diagrams showing the expression of mouse endothelial marker genes (mCd31, mCd105, mVegfr1, mVegfr2), plot on left Y axis and hVEGFA gene
plot on right Y axis. The box indicates the interquartile range, the centre horizontal line the median value and the black dots are outliers.
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on cellular lineages within the vascular system, and over-
expressed on proliferating endothelial cells [25]. These
data underline that combination of markers is required
to study the TDEC population.
Initially, VEGFRs were thought to be expressed only
on endothelial cells, but these receptors may also be ex-
pressed on tumor cells and play a role in tumor resistance
to existing therapies [5-7]. The present species-specific
real-time qRT-PCR assays combined with our series of 150
PDXs represents a powerful tool to obtain further insight
into autocrine and paracrine VEGFA-VEGR1/2 signaling in
tumorigenesis. We indeed observed human VEGFR ex-
pression in xenografts with a profile that varied
widely according to tumor types (Table 1, Figure 2c-
d): High levels of hVEGFR1 transcripts mainly observed in
colon cancers and in NSCLCs; high levels of hVEGFR2
transcripts in NSCLCs. Individually, 2 out of 5 NSCLC
xenografts (i.e.: NSCLC#3 and #5) showed more
hVEGFR2 transcripts than mVegfr2 transcripts (Table 1).
Conversely, SCLCs showed low levels of hVEGFR1 and
hVEGFR2 transcripts and CRCs showed very low levels of
hVEGFR2 transcripts (Absence in 89% of the 53 CRC
xenografts). These results identified NSCLC as an at-
tractive cancer type for anti-VEGFR2 treatment. Small-
molecule inhibitors as Sunitinib and Sorafenib are oral
multikinase inhibitors, including VEGFR2 among their
targets. The development of antibodies that can se-
lectively block VEGFR2 could potentially result in im-
proved potency or tolerability [3].
Whereras mVegfr1 and mVegfr2 expressions were ex-
tremely correlated to mouse endothelial markers (p < 10-7),
human VEGFR profiles did not correlate highly with nei-
ther hCD31 nor hCD105. Non exclusive hypotheses could
explain this observation: i) human tumor cells expressing
endothelial markers lead to VEGF- independent tumor
vascularization with no expression of VEGFR1/2 [20];
ii) VEGFRs could be also expressed on carcinoma and
participate to an essential autocrine/paracrine process
for cancer cell proliferation and survival [1].
Collectively, VEGFA/VEGFR analyses suggest several
autocrine and paracrine VEGFA-VEGFR1/2 signalings.
In additional to the classical paracrine human tumoral
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VEGFA/mouse stromal VEGFR signalling, our data
identified 3 others potential VEGFA-VEGFR signalings:
a human cancer autocrine VEGFA/VEGFR signaling, an
autocrine or paracrine mouse stromal VEGFA/VEGFR
signaling, and a paracrine mouse stromal VEGFA/
human tumoral VEGFR signaling. It is noteworthy that
the human cancer autocrine VEGFA/VEGFR signaling
could occur intracellular, as well as by VEGFA secretion
[6], limiting the quantity of extracellular VEGFA. Thus,
VEGFR small-molecule inhibitors might be a more attract-
ive therapy than VEGFA inhibitors which aim to sequester-
ing free VEGFA.
To further investigate the potential value of species-
specific PCR assays for in vivo evaluation of anti-
angiogenesis therapy in PDX models, we analyzed in the
same manner as described above, 2 NSCLC xenograft
models after treatment with bevacizumab, a recombin-
ant humanized monoclonal antibody to VEGF, approved
for cancer therapy, including in NSCLC patients. These
both models highly responded to one week-bevacizumab
treatment in monotherapy: no tumor shrinkage but
tumor stabilization throughout the experiment (Additional
file 2: Figure S1).
As expected, the levels of mCd31, mCd105, mVegfr1
and mVegfr2 transcripts were significantly lower in
the two bevacizumab-treated NSCLC xenografts as
compared to matched non-treated xenografts (Table 3).
Indeed, even if bevacizumab is able to bind and in-
hibit human VEGFA but unable to neutralize murine
VEGFA, VEGFA in these 2 xenografts is produced by
human cancer cells rather than by mouse stroma cells. It is
noteworthy that one of the two xenografts (NSCLC#3)
showed a significant upregulation of hVEGFA gene. More
interestingly, the levels of hCD31, hCD105, hVEGFR1
and hVEGFR2 transcripts were not inferior in the two
bevacizumab-treated NSCLC xenografts but on the con-
trary, hCD31 was upregulated by 3 times (p < 0.05 for
NSCLC#3) in both bevacizumab-treated xenografts. These
data suggest that the mouse endothelial cells are more
sensitive to anti-VEGFA therapy than human cells. Indeed,
cancer cells are able to take advantage of autocrine intra-
cellular VEGFA/VEGFR signalling [6] while bevacizumab
is directed against free fraction of VEGFA. Furthermore,
transdifferentiation of tumor cells into endothelial cells
has been reported to be VEGF-independent but induced
by HIF-1α [20]. Finally, bevacizumab induces hypoxia
through mouse endothelial cells destruction, which may
lead in turn to TDEC expansion. These latter results are
of interest to apprehend molecular mechanisms of bevaci-
zumab resistance.
Conclusions
The screening of a large panel of xenografts established
from various tumor types is appropriate to identify the
human tumor types that are likely to benefit from a new
targeted therapy, and next to identify predictive biomarkers
for the response to this targeted therapy. Human tumor
xenografted models, closely mimicking clinical situations in
terms of biological features and response to treatment [8],
will also provide the necessary experimental conditions to
evaluate fundamental issues in cancer, including character-
istics of metastasis, angiogenesis, and tumor-stroma inter-
actions. The present approach combining species-specific
real-time qRT-PCR assays with a large cohort of patient-
derived xenografts identified tumor endothelial cells in
the all 8 tumor types tested and also revealed a com-
plex pattern of both stroma and tumoral and both
autocrine and paracrine VEGFA-VEGFR1/2 signalings.
These both findings should be taken into account
when evaluating molecular mechanisms of resistance to
tumor anti-angiogenic strategies.
Methods
Patient-derived xenografts
Tumor xenografts have been established directly from
patient tumors and were routinely passaged by subcuta-
neous engraftment in Crl:NU(Ico)-Foxn1nu or CB17/
Icr-Prkdcscid/IcrCrl [23,24,26-31] purchased from Charles
River Laboratories (Les Arbresles, France), with protocol
and animal housing in accordance with national regulation
and international guidelines [32]. Xenografts were har-
vested here, after 5 to 12 passages into mice, when they
reached around 2,000 mg in size.
Bevacizumab (Avastin, Roche) was given i.p. twice a
week, one week, at 15 mg/kg in 0.9% NaCl. Omalizumab
(Xolair, Novartis) is given as isotypic control. Lung
carcinoma xenografts were transplanted into female
8-week-old Crl:NU(Ico)-Foxn1nu mice. Mice with tumors
of 60–200 mm3 were randomly assigned to control or
treated groups. Tumor growth was evaluated by meas-
urement of two perpendicular tumor diameters with a
caliper twice a week. Individual tumor volumes were cal-
culated: V = a × b2/2, a being the largest diameter, b the
smallest. Mice were ethically sacrificed when the tumor
volume reached 2 500 mm3 for control groups or at D29
and D50 after first injection of bevacizumab for
NSCLC#2 and NCSCLC#3, respectively.
Real-time RT-PCR
RNA extraction, cDNA synthesis and PCR conditions were
previously described [33]. The precise amount and quality
of total RNA in each reaction mix are both difficult to as-
sess. Therefore, transcripts of the TBP gene encoding the
TATA box-binding protein (a component of the DNA-
binding protein complex TFIID) were quantified as an en-
dogenous RNA control. The endogenous TBP control was
selected due to the moderate prevalence of its transcripts
and the absence of known TBP retropseudogenes
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(retropseudogenes lead to coamplification of contaminat-
ing genomic DNA and thus interfere with RT-PCR, despite
the use of primers in separate exons) [9].
Quantitative values were obtained from the cycle num-
ber (Ct value) (Perkin-Elmer Applied Biosystems, Foster
City, CA), according to the manufacturer’s manuals.
The gene primers (Additional file 1: Table S1) were
chosen using the Oligo 6.0 program (National Biosciences,
Plymouth, MN). The mouse and the human target genes
primer pairs were selected to be unique when compared to
the sequence of their respective orthologous gene. By con-
trast, a primer pair, referred as to ‘Total-TBP’ primer pair,
was selected to amplify both the mouse and the human
TBP genes. dbEST and nr databases were scanned to con-
firm the total gene specificity of the nucleotide sequences
chosen for the primers and the absence of single nucleotide
polymorphisms. To avoid amplification of contaminating
genomic DNA, one of the two primers was always placed at
the junction between two exons. Agarose gel electrophoresis
was used to verify the specificity of PCR amplicons. For each
human-specific primer pair validation, we performed no-
template control (NTC), no-human-reverse-transcriptase
control (human RT negative), mouse-reverse-transcriptase
control (mouse RT positive from a pool of normal and tu-
moral mouse RNAs extracted from various tissues types)
assays, which produced negligible signals (Ct >40), sug-
gesting that primer–dimer formation, genomic DNA con-
tamination and cross species contamination effects were
negligible. Same controls were realized for each mouse-
specific primer pair.
Statistical analysis
The distributions of mRNA levels were characterized by
their median values and ranges. Relationships between
mRNA levels of the different target genes were iden-
tified using nonparametric tests (GraphPad Prism 4.00,
GraphPad Software, San Diego, CA).
Additional files
Additional file 1: Table S1. Sequences of oligonucleotides used.
Additional file 2: Figure S1. Tumor growth curves of NSCLC#3 and
NSCLC#5 xenografts as a function of time. Mice (at least 9 per group)
were treated bevacizumab (•) at day 1 and 4; or not (o). Tumor volume
was measured twice a week. Tumor growth was evaluated by plotting
the mean of the RTV (relative tumor volume) ± SD per group over time
after first treatment.
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p-value1
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ENG/CD105 mRNA Human 29.1 (3.59-47.2) 38.2 (15.1-71.4) NS 57.64 (38.8-90.86) 57.50 (47.2 - 84.4) NS
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